Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):e603-7. doi: 10.1016/j.ijrobp.2011.09.053. Epub 2011 Dec 28.
To investigate the rates of tumor response and local control in patients with recurrent small hepatocellular carcinoma (HCC) treated with hypofractionated radiotherapy (RT) as a salvage treatment and to evaluate treatment-related toxicities.
Between 2006 and 2009, a total of 20 patients with recurrent small HCC were treated with hypofractionated RT after the failure of previous treatment. The eligibility criteria for hypofractionated RT were as follows: 1) HCC less than 5 cm, 2) HCC not adjacent to critical organs, 3) HCC without portal vein tumor thrombosis, and 4) less than 15% of normal liver volume that would be irradiated with 50% of prescribed dose. The RT dose was 50 Gy in 10 fractions. The tumor response was determined by CT scans performed 3 months after the end of RT.
The median follow-up period after RT was 22 months. The overall survival rates at 1 and 2 years were 100% and 87.9%, respectively. Complete response (CR) was achieved in seven of 20 lesions (35%) evaluated by CT scans performed 3 months after the end of RT. In-field local control was achieved in 85% of patients. Fourteen patients (70%) developed intra-hepatic metastases. Six patients developed grade 1 nausea or anorexia during RT, and two patients had progression of ascites after RT. There was no grade 3 or greater treatment-related toxicities.
The current study showed a favorable outcome with respect to hypofractionated RT for small HCC. Partial liver irradiation with 50 Gy in 10 fractions is considered tolerable without severe complications.
研究接受分割剂量放疗(RT)作为挽救治疗的复发性小肝细胞癌(HCC)患者的肿瘤反应和局部控制率,并评估与治疗相关的毒性。
2006 年至 2009 年间,共有 20 例复发性小 HCC 患者在先前治疗失败后接受分割剂量 RT 治疗。接受分割剂量 RT 的合格标准如下:1)HCC 小于 5cm,2)HCC 不紧邻关键器官,3)HCC 无门静脉肿瘤血栓形成,以及 4)50%处方剂量照射时肝脏的正常体积小于 15%。RT 剂量为 50Gy/10 次。RT 结束后 3 个月通过 CT 扫描确定肿瘤反应。
RT 后中位随访时间为 22 个月。RT 后 1 年和 2 年的总生存率分别为 100%和 87.9%。20 个可评估病灶中,有 7 个病灶(35%)通过 CT 扫描显示完全缓解(CR)。85%的患者实现了肿瘤靶区的局部控制。14 例患者(70%)发生肝内转移。6 例患者在 RT 期间出现 1 级恶心或厌食,2 例患者在 RT 后出现腹水进展。无 3 级或更高级别的与治疗相关的毒性。
目前的研究显示,分割剂量 RT 治疗小 HCC 的结果良好。50Gy/10 次的部分肝脏照射被认为是可耐受的,没有严重的并发症。